IBB 全部观点

Attention should also be paid to biotechnology companies ( IBB), as shares in this group rose by 2.6% . Note the dynamic we saw in mid- August, and much of this rise is due to Moderna's progress in DNA and other areas.

We have seen a remarkable recovery in the group as a whole after its decline, and we are now on the verge of restoring this upward trend. This is another area where we will take a look at some stocks that have declined in popularity and then reappeared.

Moving on to key areas of the market, I would like to share my thoughts on healthcare, and one of the main beneficiaries of that movement is the IBB fund. This is a biotechnology exchange-traded fund (ETF), and you can see it is in a position to trade again above its 21-week moving average .

We have a positive Relative Strength Index and a positive MACD indicator, and we will delve deeper into this area, but all the areas I mentioned, especially software, semiconductors and now biotechnology.

The reason these fields are at the forefront is that, again, semiconductors don't usually do well in a high-interest-rate environment, and the same is true for biotechnology. There is usually a sense of risk aversion, but the main driver for these three areas is innovation in artificial intelligence and new products, and we will address this as we talk.